PSORENT Features a Unique and Innovative Formulation Available Without a
Prescription Through Physicians
PRINCETON, N.J., Feb. 4 /PRNewswire/ -- NeoStrata today announced the launch of PSORENT, a clinically proven, steroid-free, topical treatment for psoriasis. PSORENT contains LCD (liquid carbonis distillate), which has proven efficacy against psoriasis symptoms, in a novel, aesthetically advanced formulation and package that promotes high patient compliance. PSORENT is available without a prescription from dermatologists beginning March 2008.
"With the launch of PSORENT, physicians will be able to offer patients a novel psoriasis treatment that reduces the unpleasant aspects of traditional coal tar therapy, resulting in high patient compliance without compromising efficacy or safety," said Barbara Green, Vice President for Technology and Clinical Affairs at NeoStrata. "PSORENT's effective and unique fast-absorbing solution applies easily and conveniently making it an ideal first-line therapy for the vast majority of psoriasis patients."
PSORENT is an aesthetically advanced, fast absorbing topical coal tar
solution that provides a new alternative for psoriasis patients and
providers. Optimally formulated with a 15 percent concentration of LCD, the
therapeutic equivalent of 2.3 percent coal tar, PSORENT is an innovative
topical solution to treat the chronic redness and scaling associated with
psoriasis. PSORENT is supplied in a convenient dab-on delivery system that
speeds LCD absorption and avoids the stains, odor and mess that are
typically associated with coal tar treatments. Additionally, the dab-on
applicator allows the patient to apply PSORENT directly to the affected
areas without touching either the solution or the skin, resulting in a
highly effective and easy to use treatment. PSORENT is available only
through physicians' offices. One 100mL bottle provides up to a 3-month
supply, at a suggested retail price
|SOURCE The NeoStrata Company|
Copyright©2008 PR Newswire.
All rights reserved